Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pulse Biosciences (PLSE) Receivables - Other (2020 - 2021)

Pulse Biosciences has reported Receivables - Other over the past 2 years, most recently at $8.4 million for Q2 2021.

  • Quarterly results put Receivables - Other at $8.4 million for Q2 2021, changed N/A from a year ago — trailing twelve months through Jun 2021 was $8.4 million (changed N/A YoY), and the annual figure for FY2020 was $1.2 million, changed.
  • Receivables - Other for Q2 2021 was $8.4 million at Pulse Biosciences, up from $1.2 million in the prior quarter.
  • Over the last five years, Receivables - Other for PLSE hit a ceiling of $8.4 million in Q2 2021 and a floor of $1.2 million in Q4 2020.